Skip to main content

Table 5 Comparison of doses to iliac and lower pelvic bone marrow (defined with 18FDG-PET) among the 4 plans

From: Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation

   Plan A Plan B Plan C Plan D p ≤ 0.05 ANOVA
Structure Parameter Mean SD(+/−) Mean SD(+/−) Mean SD(+/−) Mean SD(+/−)  
ACTIBM D max 48.19 3.11 48.34 3.22 48.77 3.21 48.68 3.37 NS
D mean 24.44 6.63 24.22 2.56 22.28 3.65 22.63 3.62 NS
V 5 96.74 4.70 96.20 6.16 95.82 6.27 95.52 6.66 NS
V 10 90.99 8.49 89.74 9.65 87.22 12.22 87.89 11.38 NS
V 15 84.31 10.64 81.75 12.04 74.75 17.13 76.28 16.98 NS
V 20 66.15 9.73 65.45 11.85 55.52 15.35 57.14 15.83 NS
V 25 45.84 8.97 46.28 9.29 37.87 11.85 37.80 12.04 NS
V 30 29.15 8.09 30.23 5.82 23.82 8.82 24.89 9.31 NS
V 35 16.43 6.62 16.82 4.14 13.33 5.82 14.75 5.98 NS
V 40 7.48 4.37 6.61 3.19 5.95 3.24 6.67 3.13 NS
V 45 0.94 1.57 0.93 1.86 1.02 1.24 1.05 1.46 NS
ACTLPBM D max 52.66 2.71 52.93 2.82 53.00 2.86 53.14 2.70 NS
D mean 33.09 4.61 30.63 4.70 29.34 4.80 29.54 4.63 NS
V 5 98.30 3.37 96.93 5.11 97.15 5.66 98.01 4.14 NS
V 10 90.09 9.01 88.32 9.85 89.50 9.28 88.95 10.05 NS
V 15 86.12 10.76 82.13 12.69 80.73 14.49 81.07 12.61 NS
V 20 82.07 12.89 76.19 13.85 71.53 15.41 72.34 14.82 NS
V 25 75.68 14.62 67.33 14.57 61.89 15.33 63.45 15.46 NS
V 30 66.78 15.38 57.91 14.86 51.34 13.93 52.29 14.28 NS
V 35 55.63 15.81 46.22 13.29 40.63 12.42 41.33 12.55 NS
V 40 38.94 12.30 32.28 10.88 29.06 10.86 29.37 10.56 NS
V 45 16.98 7.53 14.15 6.52 13.54 7.12 12.89 8.85 NS
  1. Legend: D max maximal dose, D mean mean dose, SD standard deviation, V 5,10,15,20,25,30,35,40,45 relative volume receiving 5,10,15,20,25,30,35,40,45 Gy, IBM iliac bone marrow, LPBM lower pelvis bone marrow, ACT active, A, B, C plan A, B, C, NS non significant